Sex differences in the treatment with PCSK9 monoclonal antibodies- real world experience from a dedicated preventive cardiology clinic
PCSK9 mAbs treatment demonstrated sex differences in prescription age, indications, baseline LDL-C and achievement of LDL-C goals. Adherence to PCSK9 mAb therapy was higher than previously reported, possibly due to careful surveillance strategy in a dedicated prevention clinic.
Authors
- Chen Gurevitz (ORCID: https://orcid.org/0000-0003-2632-6669)
- Ran Kornowski (ORCID: https://orcid.org/0000-0002-7708-8253)
- Alon Eisen (ORCID: https://orcid.org/0000-0003-0440-1648)
- Aviad Rotholz (ORCID: https://orcid.org/0009-0008-0087-6746)
- Lital Hodeda (ORCID: https://orcid.org/0009-0002-7436-7836)
Institutions
- Bar-Ilan University (IL)
- Tel Aviv University (IL)
- Rabin Medical Center (IL)
- Mount Sinai Hospital (US)
- Mount Sinai Hospital (US)
Publication Details
- Journal
- American Journal of Preventive Cardiology
- Published
- 2025-06-22
- DOI
- https://doi.org/10.1016/j.ajpc.2025.101022
- Citations
- 2
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 4.01